Johan W Mouton

List of Publications by Citations

274 papers	12,647 citations	58 h-index	101 g-index
280 ext. papers	14,908 ext. citations	6.6 avg, IF	6.37 L-index

#	Paper	IF	Citations
274	Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. *Lancet Infectious Diseases, The*, **2014**, 14, 498-509	25.5	534
273	Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. *Journal of Antimicrobial Chemotherapy*, **2005**, 55, 601-7	5.1	387
272	EUCAST expert rules in antimicrobial susceptibility testing. *Clinical Microbiology and Infection*, **2013**, 19, 141-60	9.5	386
271	Current evidence on hospital antimicrobial stewardship objectives: a systematic review and meta-analysis. *Lancet Infectious Diseases, The*, **2016**, 16, 847-856	25.5	352
270	International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-Infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). *Pharmacotherapy*, **2019**, 39, 10-39	5.8	280
269	Tissue concentrations: do we ever learn?. *Journal of Antimicrobial Chemotherapy*, **2008**, 61, 235-7	5.1	274
268	European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria. *Journal of Antimicrobial Chemotherapy*, **2003**, 52, 145-8	5.1	266
267	Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. *Lancet Infectious Diseases, The*, **2018**, 18, 391-400	25.5	255
266	In vitro susceptibilities of zygomycetes to conventional and new antifungals. *Journal of Antimicrobial Chemotherapy*, **2003**, 51, 45-52	5.1	246
265	In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. *Antimicrobial Agents and Chemotherapy*, **2002**, 46, 62-8	5.9	205
264	In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. *Antimicrobial Agents and Chemotherapy*, **2003**, 47, 106-17	5.9	204
263	Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria. *Drug Resistance Updates*, **2012**, 15, 149-61	23.2	197
262	Use of a novel panel of nine short tandem repeats for exact and high-resolution fingerprinting of Aspergillus fumigatus isolates. *Journal of Clinical Microbiology*, **2005**, 43, 4112-20	9.7	192
261	Reduction of Surgical-Site Infections in Cardiothoracic Surgery by Elimination of Nasal Carriage of Staphylococcus aureus. *Infection Control and Hospital Epidemiology*, **1996**, 17, 780-785	2	188
260	Protein binding: do we ever learn?. *Antimicrobial Agents and Chemotherapy*, **2011**, 55, 3067-74	5.9	181
259	The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach. *Clinical Microbiology and Infection*, **2012**, 18, E37-45	9.5	180
258	Comparison of NCCLS and 3-(4,5-dimethyl-2-Thiazyl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) methods of in vitro susceptibility testing of filamentous fungi and development of a new simplified method. *Journal of Clinical Microbiology*, **2000**, 38, 2949-54	9.7	175

257	MIC-based dose adjustment: facts and fables. *Journal of Antimicrobial Chemotherapy*, **2018**, 73, 564-568	5.1	150
256	The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. *American Journal of Respiratory and Critical Care Medicine*, **2012**, 186, 559-65	10.2	146
255	Colorimetric assay for antifungal susceptibility testing of Aspergillus species. *Journal of Clinical Microbiology*, **2001**, 39, 3402-8	9.7	142
254	Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective. *Drug Resistance Updates*, **2011**, 14, 107-17	23.2	141
253	Comparative pharmacokinetics of the carbapenems: clinical implications. *Clinical Pharmacokinetics*, **2000**, 39, 185-201	6.2	140
252	Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials. *Journal of Antimicrobial Chemotherapy*, **2015**, 70, 2456-64	5.1	127
251	Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink?. *Journal of Antimicrobial Chemotherapy*, **2010**, 65, 2141-8	5.1	117
250	European Committee on Antimicrobial Susceptibility Testing (EUCAST) Technical Notes on antimicrobial susceptibility testing. *Clinical Microbiology and Infection*, **2006**, 12, 501-3	9.5	114
249	Aspergillus and aspergilloses in wild and domestic animals: a global health concern with parallels to human disease. *Medical Mycology*, **2015**, 53, 765-97	3.9	111
248	Therapeutic drug monitoring of voriconazole. *Therapeutic Drug Monitoring*, **2008**, 30, 403-11	3.2	107
247	Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. *Antimicrobial Agents and Chemotherapy*, **2010**, 54, 860-5	5.9	105
246	Pharmacokinetic/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration. *Clinical Pharmacokinetics*, **2005**, 44, 201-10	6.2	105
245	Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia. *Antimicrobial Agents and Chemotherapy*, **2007**, 51, 3599-604	5.9	104
244	Vancomycin: pharmacokinetics and administration regimens in neonates. *Clinical Pharmacokinetics*, **2004**, 43, 417-40	6.2	102
243	Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women: A Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2018**, 319, 1781-1789	27.4	99
242	Applying pharmacokinetic/pharmacodynamic principles in critically ill patients: optimizing efficacy and reducing resistance development. *Seminars in Respiratory and Critical Care Medicine*, **2015**, 36, 136-53	3.9	93
241	In vitro interaction of terbinafine with itraconazole against clinical isolates of Scedosporium prolificans. *Antimicrobial Agents and Chemotherapy*, **2000**, 44, 470-2	5.9	88
240	Reduced subcutaneous tissue distribution of cefazolin in morbidly obese versus non-obese patients determined using clinical microdialysis. *Journal of Antimicrobial Chemotherapy*, **2014**, 69, 715-23	5.1	86

239	Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia. *Journal of Antimicrobial Chemotherapy*, **2013**, 68, 900-6	5.1	86
238	Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs. *International Journal of Antimicrobial Agents*, **2002**, 19, 355-8	14.3	83
237	Consumption of antimicrobials in pigs, veal calves, and broilers in the Netherlands: quantitative results of nationwide collection of data in 2011. *PLoS ONE*, **2013**, 8, e77525	3.7	82
236	Continuous infusion of beta-lactams. *Current Opinion in Critical Care*, **2007**, 13, 598-606	3.5	81
235	Assessing in vitro combinations of antifungal drugs against yeasts and filamentous fungi: comparison of different drug interaction models. *Medical Mycology*, **2005**, 43, 133-52	3.9	80
234	Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis. *Antimicrobial Agents and Chemotherapy*, **2010**, 54, 4758-64	5.9	76
233	The role of azoles in the management of azole-resistant aspergillosis: from the bench to the bedside. *Drug Resistance Updates*, **2014**, 17, 37-50	23.2	74
232	Forgotten antibiotics: an inventory in Europe, the United States, Canada, and Australia. *Clinical Infectious Diseases*, **2012**, 54, 268-74	11.6	71
231	Invasive Aspergillosis by : Epidemiology, Diagnosis, Antifungal Resistance, and Management. *Journal of Fungi (Basel, Switzerland)*, **2019**, 5,	5.6	70
230	Meropenem clinical pharmacokinetics. *Clinical Pharmacokinetics*, **1995**, 28, 275-86	6.2	70
229	Black yeasts and their filamentous relatives: principles of pathogenesis and host defense. *Clinical Microbiology Reviews*, **2014**, 27, 527-42	34	69
228	Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 368-75	5.9	68
227	New dosing strategies for antibacterial agents in the neonate. *Seminars in Fetal and Neonatal Medicine*, **2005**, 10, 185-94	3.7	68
226	Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141. *Antimicrobial Agents and Chemotherapy*, **2004**, 48, 1713-8	5.9	68
225	Comparison of spectrophotometric and visual readings of NCCLS method and evaluation of a colorimetric method based on reduction of a soluble tetrazolium salt, 2,3-bis [2-methoxy-4-nitro-5-[(sulfenylamino) carbonyl]-2H-tetrazolium-hydroxide], for antifungal susceptibility testing of Aspergillus species. *Journal of Clinical Microbiology*, **2001**, 39, 4256-63	9.7	67
224	Clofazimine Prevents the Regrowth of Mycobacterium abscessus and Mycobacterium avium Type Strains Exposed to Amikacin and Clarithromycin. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 1097-105	5.9	64
223	EUCAST technical note on tigecycline. *Clinical Microbiology and Infection*, **2006**, 12, 1147-9	9.5	64
222	Reviving old antibiotics. *Journal of Antimicrobial Chemotherapy*, **2015**, 70, 2177-81	5.1	62

221	Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. *Journal of Antimicrobial Chemotherapy*, **2008**, 61, 382-8	5.1	61
220	Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo. *Antimicrobial Agents and Chemotherapy*, **1999**, 43, 2473-8	5.9	61
219	Emergence of antibiotic resistance amongst Pseudomonas aeruginosa isolates from patients with cystic fibrosis. *Journal of Antimicrobial Chemotherapy*, **1993**, 31, 919-26	5.1	61
218	Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis. *Journal of Antimicrobial Chemotherapy*, **2013**, 68, 385-93	5.1	58
217	Treatment Outcomes of Colistin- and Carbapenem-resistant Acinetobacter baumannii Infections: An Exploratory Subgroup Analysis of a Randomized Clinical Trial. *Clinical Infectious Diseases*, **2019**, 69, 769-776	11.6	58
216	Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis. *Expert Review of Anti-Infective Therapy*, **2013**, 11, 931-41	5.5	56
215	Clinical applications of population pharmacokinetic models of antibiotics: Challenges and perspectives. *Pharmacological Research*, **2018**, 134, 280-288	10.2	55
214	Breakpoints: current practice and future perspectives. *International Journal of Antimicrobial Agents*, **2002**, 19, 323-31	14.3	55
213	Vancomycin population pharmacokinetics in neonates. *Clinical Pharmacology and Therapeutics*, **2000**, 67, 360-7	6.1	55
212	Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Current practice and suggestions for future directions. *Clinical Pharmacokinetics*, **1998**, 35, 437-59	6.2	55
211	Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 2855-66	5.9	52
210	Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	52
209	Pharmacodynamics of tobramycin in patients with cystic fibrosis. *Diagnostic Microbiology and Infectious Disease*, **2005**, 52, 123-7	2.9	52
208	Potent synergistic in vitro interaction between nonantimicrobial membrane-active compounds and itraconazole against clinical isolates of Aspergillus fumigatus resistant to itraconazole. *Antimicrobial Agents and Chemotherapy*, **2004**, 48, 1335-43	5.9	52
207	Consistent global approach on reporting of colistin doses to promote safe and effective use. *Clinical Infectious Diseases*, **2014**, 58, 139-41	11.6	51
206	Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo. *Antimicrobial Agents and Chemotherapy*, **2007**, 51, 3449-51	5.9	51
205	Temocillin (6 g daily) in critically ill patients: continuous infusion versus three times daily administration. *Journal of Antimicrobial Chemotherapy*, **2015**, 70, 891-8	5.1	50
204	Azole-resistant Aspergillus fumigatus, Iran. *Emerging Infectious Diseases*, **2013**, 19, 832-4	10.2	50

203	A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unit. *Clinical Therapeutics*, **2005**, 27, 762-72	3.5	50
202	Use of pharmacodynamic parameters to predict efficacy of combination therapy by using fractional inhibitory concentration kinetics. *Antimicrobial Agents and Chemotherapy*, **1998**, 42, 744-8	5.9	50
201	Time-kill kinetics of antibiotics active against rapidly growing mycobacteria. *Journal of Antimicrobial Chemotherapy*, **2015**, 70, 811-7	5.1	49
200	Extensive genetic diversity within the Dutch clinical Cryptococcus neoformans population. *Journal of Clinical Microbiology*, **2012**, 50, 1918-26	9.7	49
199	Comparison of the Etest and the sensititre colorimetric methods with the NCCLS proposed standard for antifungal susceptibility testing of Aspergillus species. *Journal of Clinical Microbiology*, **2002**, 40, 2876-85	9.7	49
198	Population pharmacokinetic analysis of nonlinear behavior of piperacillin during intermittent or continuous infusion in patients with cystic fibrosis. *Antimicrobial Agents and Chemotherapy*, **2003**, 47, 541-7	5.9	48
197	Molecular detection of the macrolide efflux gene: to discriminate or not to discriminate between mef(A) and mef(E). *Antimicrobial Agents and Chemotherapy*, **2005**, 49, 1271-8	5.9	48
196	Efficacy of antifungal therapy in a nonneutropenic murine model of zygomycosis. *Antimicrobial Agents and Chemotherapy*, **2002**, 46, 1953-9	5.9	47
195	A Novel Y319H Substitution in CYP51C Associated with Azole Resistance in Aspergillus flavus. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 6615-9	5.9	45
194	Inhaled antibiotics: dry or wet?. *European Respiratory Journal*, **2014**, 44, 1308-18	13.6	44
193	Pulmonary surfactant as vehicle for intratracheally instilled tobramycin in mice infected with Klebsiella pneumoniae. *British Journal of Pharmacology*, **1996**, 119, 1145-8	8.6	44
192	Towards Rational Dosing Algorithms for Vancomycin in Neonates and Infants Based on Population Pharmacokinetic Modeling. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 1013-21	5.9	43
191	Review of the pharmacokinetic properties of nitrofurantoin and nitroxoline. *Journal of Antimicrobial Chemotherapy*, **2018**, 73, 2916-2926	5.1	43
190	In vitro susceptibility of 188 clinical and environmental isolates of Aspergillus flavus for the new triazole isavuconazole and seven other antifungal drugs. *Mycoses*, **2011**, 54, e583-9	5.2	43
189	Comparison of pharmacodynamics of azithromycin and erythromycin in vitro and in vivo. *Antimicrobial Agents and Chemotherapy*, **1998**, 42, 377-82	5.9	43
188	Tobramycin population pharmacokinetics in neonates. *Clinical Pharmacology and Therapeutics*, **1997** , 62, 392-9	6.1	42
187	Variation of MIC measurements: the contribution of strain and laboratory variability to measurement precision. *Journal of Antimicrobial Chemotherapy*, **2018**, 73, 2374-2379	5.1	42
186	Wild-type MIC distribution and epidemiological cut-off values in clinical Legionella pneumophila serogroup 1 isolates. *Diagnostic Microbiology and Infectious Disease*, **2012**, 72, 103-8	2.9	41

185	Impact of pharmacodynamics on breakpoint selection for susceptibility testing. *Infectious Disease Clinics of North America*, **2003**, 17, 579-98	6.5	41
184	Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation. *Antimicrobial Agents and Chemotherapy*, **2007**, 51, 3049-55	5.9	40
183	Pharmacokinetics of meropenem in serum and suction blister fluid during continuous and intermittent infusion. *Journal of Antimicrobial Chemotherapy*, **1991**, 28, 911-8	5.1	39
182	Tigecycline Is Highly Efficacious against Mycobacterium abscessus Pulmonary Disease. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 2895-900	5.9	39
181	Novel model-based dosing guidelines for gentamicin and tobramycin in preterm and term neonates. *Journal of Antimicrobial Chemotherapy*, **2015**, 70, 2074-7	5.1	38
180	Ciprofloxacin in polyethylene glycol-coated liposomes: efficacy in rat models of acute or chronic Pseudomonas aeruginosa infection. *Antimicrobial Agents and Chemotherapy*, **2002**, 46, 2575-81	5.9	38
179	Resistance of Asian Cryptococcus neoformans serotype A is confined to few microsatellite genotypes. *PLoS ONE*, **2012**, 7, e32868	3.7	38
178	Non-linear absorption pharmacokinetics of amoxicillin: consequences for dosing regimens and clinical breakpoints. *Journal of Antimicrobial Chemotherapy*, **2016**, 71, 2909-17	5.1	37
177	Failure of the Amikacin, Cefoxitin, and Clarithromycin Combination Regimen for Treating Pulmonary Mycobacterium abscessus Infection. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 6374-6	5.9	36
176	Pharmacodynamics and dose-response relationships of liposomal amphotericin B against different azole-resistant Aspergillus fumigatus isolates in a murine model of disseminated aspergillosis. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 1866-71	5.9	36
175	In vitro activity of isavuconazole against 208 Aspergillus flavus isolates in comparison with 7 other antifungal agents: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. *Diagnostic Microbiology and Infectious Disease*, **2011**, 71, 370-7	2.9	36
174	Pharmacokinetics and penetration of ceftazidime and avibactam into epithelial lining fluid in thigh- and lung-infected mice. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 2299-304	5.9	35
173	Pneumolysin is a key factor in misidentification of macrolide-resistant Streptococcus pneumoniae and is a putative virulence factor of S. mitis and other streptococci. *Journal of Clinical Microbiology*, **2004**, 42, 4355-7	9.7	35
172	Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases. *Expert Review of Anti-Infective Therapy*, **2015**, 13, 9-27	5.5	34
171	Isolation of ciprofloxacin-resistant Legionella pneumophila in a patient with severe pneumonia. *Journal of Antimicrobial Chemotherapy*, **2014**, 69, 2869-71	5.1	34
170	Failure of posaconazole therapy in a renal transplant patient with invasive aspergillosis due to Aspergillus fumigatus with attenuated susceptibility to posaconazole. *Antimicrobial Agents and Chemotherapy*, **2011**, 55, 3564-6	5.9	34
169	Improved efficacy of ciprofloxacin administered in polyethylene glycol-coated liposomes for treatment of Klebsiella pneumoniae pneumonia in rats. *Antimicrobial Agents and Chemotherapy*, **2001**, 45, 1487-92	5.9	34
168	Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol. *BMJ Open*, **2016**, 6, e009956	3	34

167	Global survey of polymyxin use: A call for international guidelines. *Journal of Global Antimicrobial Resistance*, **2013**, 1, 131-134	3.4	33
166	Combination chemotherapy for the treatment of invasive infections by Scedosporium prolificans. *Clinical Microbiology and Infection*, **2000**, 6, 336-7	9.5	33
165	Multicentre validation of 4-well azole agar plates as a screening method for detection of clinically relevant azole-resistant Aspergillus fumigatus. *Journal of Antimicrobial Chemotherapy*, **2017**, 72, 3325-3333	5.1	32
164	Pharmacodynamics of imipenem in combination with β-lactamase inhibitor MK7655 in a murine thigh model. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 790-5	5.9	32
163	In vitro interaction of voriconazole and anidulafungin against triazole-resistant Aspergillus fumigatus. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 796-803	5.9	32
162	Chlamydia antibody testing and diagnosing tubal pathology in subfertile women: an individual patient data meta-analysis. *Human Reproduction Update*, **2011**, 17, 301-10	15.8	32
161	Pharmacokinetics of clindamycin in pregnant women in the peripartum period. *Antimicrobial Agents and Chemotherapy*, **2010**, 54, 2175-81	5.9	31
160	Extended-interval dosing of tobramycin in neonates: implications for therapeutic drug monitoring. *Clinical Pharmacology and Therapeutics*, **2002**, 71, 349-58	6.1	31
159	Amikacin Pharmacokinetics/Pharmacodynamics in a Novel Hollow-Fiber Mycobacterium abscessus Disease Model. *Antimicrobial Agents and Chemotherapy*, **2015**, 60, 1242-8	5.9	30
158	The fate of inhaled antibiotics after deposition in cystic fibrosis: How to get drug to the bug?. *Journal of Cystic Fibrosis*, **2017**, 16, 13-23	4.1	30
157	Duration and clinical relevance of postantibiotic effect in relation to the dosing interval. *Antimicrobial Agents and Chemotherapy*, **1998**, 42, 749-54	5.9	30
156	In vitro activity of ceftazidime-avibactam combination in in vitro checkerboard assays. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 1138-44	5.9	28
155	Diagnostic and medical needs for therapeutic drug monitoring of antibiotics. *European Journal of Clinical Microbiology and Infectious Diseases*, **2020**, 39, 791-797	5.3	28
154	European Society of clinical microbiology and infectious diseases (ESCMID) guidelines for the treatment of infections caused by Multidrug-resistant Gram-negative bacilli (endorsed by ESICM -European Society of intensive care Medicine).. *Clinical Microbiology and Infection*, **2021**,	9.5	27
153	Combination of pantothenamides with vanin inhibitors as a novel antibiotic strategy against gram-positive bacteria. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 4794-800	5.9	26
152	Susceptibility of ESBL Escherichia coli and Klebsiella pneumoniae to fosfomycin in the Netherlands and comparison of several testing methods including Etest, MIC test strip, Vitek2, Phoenix and disc diffusion. *Journal of Antimicrobial Chemotherapy*, **2018**, 73, 2380-2387	5.1	25
151	Monte Carlo simulations based on phase 1 studies predict target attainment of ceftobiprole in nosocomial pneumonia patients: a validation study. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 2047-53	5.9	25
150	Concentration-dependency of beta-lactam-induced filament formation in Gram-negative bacteria. *Clinical Microbiology and Infection*, **2008**, 14, 344-9	9.5	25

149	EUCAST Technical Note on daptomycin. *Clinical Microbiology and Infection*, **2006**, 12, 599-601	9.5	25
148	Exogenous pulmonary surfactant as a drug delivering agent: influence of antibiotics on surfactant activity. *British Journal of Pharmacology*, **1996**, 118, 593-8	8.6	25
147	Antifungal Susceptibility Testing of Candida Isolates with the EUCAST Methodology, a New Method for ECOFF Determination. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	23
146	Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model. *Journal of Antimicrobial Chemotherapy*, **2014**, 69, 1611-9	5.1	23
145	Amphotericin B- and voriconazole-echinocandin combinations against Aspergillus spp.: Effect of serum on inhibitory and fungicidal interactions. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 4656-63	5.9	23
144	Effect of treatment duration on pharmacokinetic/pharmacodynamic indices correlating with therapeutic efficacy of ceftazidime in experimental Klebsiella pneumoniae lung infection. *Antimicrobial Agents and Chemotherapy*, **2006**, 50, 2919-25	5.9	22
143	Pharmacokinetics of penicillin G in infants with a gestational age of less than 32 weeks. *Antimicrobial Agents and Chemotherapy*, **2007**, 51, 3720-5	5.9	22
142	Effect of dosing and dosing frequency on the efficacy of ceftizoxime and the emergence of ceftizoxime resistance during the early development of murine abscesses caused by Bacteroides fragilis and Enterobacter cloacae mixed infection. *Antimicrobial Agents and Chemotherapy*, **2007**, 51, 3605-11	5.9	22
141	Method for measuring postantifungal effect in Aspergillus species. *Antimicrobial Agents and Chemotherapy*, **2002**, 46, 1960-5	5.9	22
140	Pharmacodynamics of Ceftolozane Combined with Tazobactam against Enterobacteriaceae in a Neutropenic Mouse Thigh Model. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 7272-7279	5.9	22
139	Shortening the incubation time for antimicrobial susceptibility testing by disk diffusion for Enterobacteriaceae: how short can it be and are the results accurate?. *International Journal of Antimicrobial Agents*, **2017**, 49, 631-637	14.3	21
138	Fosfomycin efficacy and emergence of resistance among Enterobacteriaceae in an in vitro dynamic bladder infection model. *Journal of Antimicrobial Chemotherapy*, **2018**, 73, 709-719	5.1	21
137	Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs. *Journal of Antimicrobial Chemotherapy*, **2018**, 73, 134-142	5.1	21
136	Continuous administration of PBP-2- and PBP-3-specific beta-lactams causes higher cytokine responses in murine Pseudomonas aeruginosa and Escherichia coli sepsis. *Journal of Antimicrobial Chemotherapy*, **2007**, 59, 926-33	5.1	21
135	In vitro activities of pentamidine, pyrimethamine, trimethoprim, and sulfonamides against Aspergillus species. *Antimicrobial Agents and Chemotherapy*, **2002**, 46, 2029-31	5.9	21
134	An alternative strategy for combination therapy: Interactions between polymyxin B and non-antibiotics. *International Journal of Antimicrobial Agents*, **2019**, 53, 34-39	14.3	21
133	Time-kill kinetics of slowly growing mycobacteria common in pulmonary disease. *Journal of Antimicrobial Chemotherapy*, **2015**, 70, 2838-43	5.1	20
132	Antimicrobial prescription patterns of veterinarians: introduction of a benchmarking approach. *Journal of Antimicrobial Chemotherapy*, **2015**, 70, 2423-5	5.1	20

131	A fast and sensitive LC-MS/MS method for the quantification of fosfomycin in human urine and plasma using one sample preparation method and HILIC chromatography. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2017**, 1061-1062, 263-269	3.2	20
130	The strength of synergistic interaction between posaconazole and caspofungin depends on the underlying azole resistance mechanism of Aspergillus fumigatus. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 1738-44	5.9	20
129	The influence of labour on the pharmacokinetics of intravenously administered amoxicillin in pregnant women. *British Journal of Clinical Pharmacology*, **2008**, 66, 866-74	3.8	20
128	Pharmacodynamics of fosfomycin against ESBL- and/or carbapenemase-producing Enterobacteriaceae. *Journal of Antimicrobial Chemotherapy*, **2017**, 72, 3374-3381	5.1	19
127	Genetic Variation in TLR10, an Inhibitory Toll-Like Receptor, Influences Susceptibility to Complicated Skin and Skin Structure Infections. *Journal of Infectious Diseases*, **2015**, 212, 1491-9	7	19
126	Posaconazole prophylaxis in experimental azole-resistant invasive pulmonary aspergillosis. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 1487-94	5.9	19
125	In Vitro Activity of Ceftolozane Alone and in Combination with Tazobactam against Extended-Spectrum-β-Lactamase-Harboring Enterobacteriaceae. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 4521-5	5.9	19
124	Which cephalosporin for gonorrhoea?. *Sexually Transmitted Infections*, **2004**, 80, 386-8	2.8	19
123	Comparative study of the effects of ceftizoxime, piperacillin, and piperacillin-tazobactam concentrations on antibacterial activity and selection of antibiotic-resistant mutants of Enterobacter cloacae and Bacteroides fragilis in vitro and in vivo in mixed-infection abscesses. *Antimicrobial Agents and Chemotherapy*, **2004**, 48, 1688-98	5.9	19
122	Aerosol therapy in cystic fibrosis: a survey of 54 CF centers. *Pediatric Pulmonology*, **2000**, 30, 368-76	3.5	19
121	Lung clearance of intratracheally instilled 99mTc-tobramycin using pulmonary surfactant as vehicle. *British Journal of Pharmacology*, **1999**, 126, 1091-6	8.6	19
120	Moxifloxacin's Limited Efficacy in the Hollow-Fiber Model of Mycobacterium abscessus Disease. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 3779-85	5.9	19
119	Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes. *Clinical Microbiology and Infection*, **2020**, 26, 1185-1191	9.5	18
118	Synergistic activity of rifampicin and ethambutol against slow-growing nontuberculous mycobacteria is currently of questionable clinical significance. *International Journal of Antimicrobial Agents*, **2013**, 42, 80-2	14.3	18
117	Inhibitory and fungicidal effects of antifungal drugs against Aspergillus species in the presence of serum. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 1625-31	5.9	18
116	Clinical impact of preincubation of blood cultures at 37°C. *Journal of Clinical Microbiology*, **2011**, 49, 275-80	9.7	18
115	In vitro activities at pH 5.0 and pH 7.0 and in vivo efficacy of flucytosine against Aspergillus fumigatus. *Antimicrobial Agents and Chemotherapy*, **2008**, 52, 4483-5	5.9	18
114	The epidemiology of vaginal colonisation with group B streptococci in a sexually transmitted disease clinic. *European Journal of Obstetrics, Gynecology and Reproductive Biology*, **2002**, 105, 177-80	2.4	18

113	Population pharmacokinetics of vancomycin in obesity: Finding the optimal dose for (morbidly) obese individuals. *British Journal of Clinical Pharmacology*, **2020**, 86, 303-317	3.8	18
112	Relationship between minimum inhibitory concentration and stationary concentration revisited: growth rates and minimum bactericidal concentrations. *Clinical Pharmacokinetics*, **2005**, 44, 767-8	6.2	17
111	Guide-free Cas9 from pathogenic bacteria causes severe damage to DNA. *Science Advances*, **2020**, 6, eaaz4849	14.1	16
110	Exploring colistin pharmacodynamics against Klebsiella pneumoniae: a need to revise current susceptibility breakpoints. *Journal of Antimicrobial Chemotherapy*, **2018**, 73, 953-961	5.1	16
109	Dose optimization of voriconazole/anidulafungin combination against Aspergillus fumigatus using an in vitro pharmacokinetic/pharmacodynamic model and response surface analysis: clinical implications for azole-resistant aspergillosis. *Journal of Antimicrobial Chemotherapy*, **2016**, 71, 3135-3147	5.1	16
108	Composite survival index to compare virulence changes in azole-resistant Aspergillus fumigatus clinical isolates. *PLoS ONE*, **2013**, 8, e72280	3.7	16
107	In vivo efficacy of trovafloxacin against Bacteroides fragilis in mixed infection with either Escherichia coli or a vancomycin-resistant strain of Enterococcus faecium in an established-abscess murine model. *Antimicrobial Agents and Chemotherapy*, **2001**, 45, 1394-401	5.9	16
106	In vitro susceptibilities of Zygomycota to polyenes. *Journal of Antimicrobial Chemotherapy*, **2002**, 49, 741-4	5.1	16
105	Typing of Pseudomonas aeruginosa strains from patients with cystic fibrosis: phenotyping versus genotyping. *Clinical Microbiology and Infection*, **1996**, 1, 261-265	9.5	16
104	Antibacterial therapy in cystic fibrosis. *Medical Clinics of North America*, **1990**, 74, 837-50	7	16
103	Pharmacodynamics of anidulafungin against clinical Aspergillus fumigatus isolates in a nonneutropenic murine model of disseminated aspergillosis. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 303-8	5.9	15
102	Amoxicillin pharmacokinetics in pregnant women with preterm premature rupture of the membranes. *American Journal of Obstetrics and Gynecology*, **2008**, 198, 108.e1-6	6.4	15
101	Methodological features of clinical pharmacokinetic-pharmacodynamic studies of antibacterials and antifungals: a systematic review. *Journal of Antimicrobial Chemotherapy*, **2020**, 75, 1374-1389	5.1	14
100	Pharmacodynamics and differential activity of nitrofurantoin against ESBL-positive pathogens involved in urinary tract infections. *Journal of Antimicrobial Chemotherapy*, **2016**, 71, 2883-9	5.1	14
99	Pharmacodynamics of Voriconazole against Wild-Type and Azole-Resistant Aspergillus flavus Isolates in a Nonneutropenic Murine Model of Disseminated Aspergillosis. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	14
98	Pharmacokinetics of amoxicillin in maternal, umbilical cord, and neonatal sera. *Antimicrobial Agents and Chemotherapy*, **2009**, 53, 1574-80	5.9	14
97	The DUEL study: a multi-center in vitro evaluation of linezolid compared with other antibiotics in the Netherlands. *Clinical Microbiology and Infection*, **2001**, 7, 486-91	9.5	14
96	Successful treatment of azole-resistant invasive aspergillosis in a bottlenose dolphin with high-dose posaconazole. *Medical Mycology Case Reports*, **2017**, 16, 16-19	1.7	13

95	Highly variable absorption of clavulanic acid during the day: a population pharmacokinetic analysis. *Journal of Antimicrobial Chemotherapy*, **2018**, 73, 469-476	5.1	13
94	Evaluation of the post-antifungal effect (PAFE) of amphotericin B and nystatin against 30 zygomycetes using two different media. *Journal of Antimicrobial Chemotherapy*, **2003**, 52, 65-70	5.1	13
93	Antimicrobial susceptibility testing of Mycobacterium tuberculosis complex isolates - the EUCAST broth microdilution reference method for MIC determination. *Clinical Microbiology and Infection*, **2020**, 26, 1488-1492	9.5	13
92	Pharmacokinetics and Pharmacodynamics of Murepavadin in Neutropenic Mouse Models. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	13
91	EUCAST testing of Isavuconazole susceptibility in Aspergillus: comparison of results for Inoculum standardization using Conidium counting versus optical density. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 6432-6	5.9	12
90	A structural comparison of lipopolysaccharide biosynthesis loci of Legionella pneumophila serogroup 1 strains. *BMC Microbiology*, **2013**, 13, 198	4.5	12
89	Correlation of MIC value and disk inhibition zone diameters in clinical Legionella pneumophila serogroup 1 isolates. *Diagnostic Microbiology and Infectious Disease*, **2013**, 76, 339-42	2.9	12
88	Effect of a single percutaneous abscess drainage puncture and imipenem therapy, alone or in combination, in treatment of mixed-infection abscesses in mice. *Antimicrobial Agents and Chemotherapy*, **2002**, 46, 3712-8	5.9	12
87	Patient-specific modelling of regional tobramycin concentration levels in airways of patients with cystic fibrosis: can we dose once daily?. *Journal of Antimicrobial Chemotherapy*, **2017**, 72, 3435-3442	5.1	11
86	Intrapulmonary posaconazole penetration at the infection site in an immunosuppressed murine model of invasive pulmonary aspergillosis receiving oral prophylactic regimens. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 2964-7	5.9	11
85	Methodological issues related to antifungal drug interaction modelling for filamentous fungi. *Reviews in Medical Microbiology*, **2002**, 13, 101-117	1.1	11
84	The stability of antimycobacterial drugs in media used for drug susceptibility testing. *Diagnostic Microbiology and Infectious Disease*, **2018**, 92, 305-308	2.9	11
83	Optimizing dosing of nitrofurantoin from a PK/PD point of view: What do we need to know?. *Drug Resistance Updates*, **2019**, 43, 1-9	23.2	10
82	Assessment of efficacy of antifungals in experimental models of invasive aspergillosis in an era of emerging resistance: the value of real-time quantitative PCR. *Current Opinion in Pharmacology*, **2011**, 11, 486-93	5.1	10
81	Evaluation of Etest to determine tigecycline MICs for Enterobacter species. *Antimicrobial Agents and Chemotherapy*, **2010**, 54, 2746-7	5.9	10
80	Method for phenotypic detection of extended-spectrum beta-lactamases in enterobacter species in the routine clinical setting. *Journal of Clinical Microbiology*, **2011**, 49, 2711-3	9.7	10
79	Impact of bacterial species and baseline resistance on fosfomycin efficacy in urinary tract infections. *Journal of Antimicrobial Chemotherapy*, **2020**, 75, 988-996	5.1	10
78	Pharmacodynamics of nitrofurantoin at different pH levels against pathogens involved in urinary tract infections. *Journal of Antimicrobial Chemotherapy*, **2017**, 72, 3366-3373	5.1	9

77	Oral Fosfomycin Treatment for Enterococcal Urinary Tract Infections in a Dynamic Model. *Antimicrobial Agents and Chemotherapy*, **2020**, 64,	5.9	9
76	Pharmacodynamics of Cefepime Combined with Tazobactam against Clinically Relevant Enterobacteriaceae in a Neutropenic Mouse Thigh Model. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	9
75	The therapeutic effect of tigecycline, unlike that of Ceftazidime, is not influenced by whether the Klebsiella pneumoniae strain produces extended-spectrum β-lactamases in experimental pneumonia in rats. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 643-6	5.9	9
74	Dose-response relationships of three amphotericin B formulations in a non-neutropenic murine model of invasive aspergillosis. *Medical Mycology*, **2009**, 47, 802-7	3.9	9
73	Applying Pharmacodynamics for Susceptibility Breakpoint Selection and Susceptibility Testing. *Infectious Disease and Therapy*, **2007**, 21-44		9
72	Hydrogen cyanide emission in the lung by Staphylococcus aureus. *European Respiratory Journal*, **2016**, 48, 577-9	13.6	9
71	Soup with or without meatballs: Impact of nutritional factors on the MIC, kill-rates and growth-rates. *European Journal of Pharmaceutical Sciences*, **2018**, 125, 23-27	5.1	9
70	Tobramycin Clearance Is Best Described by Renal Function Estimates in Obese and Non-obese Individuals: Results of a Prospective Rich Sampling Pharmacokinetic Study. *Pharmaceutical Research* , **2019**, 36, 112	4.5	8
69	EUCAST Technical Note on linezolid. *Clinical Microbiology and Infection*, **2006**, 12, 1243-5	9.5	8
68	Amplified fragment length polymorphism fingerprinting is an effective technique to distinguish streptococcus pneumoniae from other Streptococci and an efficient alternative to pulsed-field gel electrophoresis for molecular typing of pneumococci. *Journal of Clinical Microbiology*, **2004**, 42, 369-71	9.7	8
67	Oral Fosfomycin Efficacy with Variable Urinary Exposures following Single and Multiple Doses against : the Importance of Heteroresistance for Growth Outcome. *Antimicrobial Agents and Chemotherapy*, **2020**, 64,	5.9	8
66	Triple combination of meropenem, colistin and tigecycline was bactericidal in a dynamic model despite mere additive interactions in chequerboard assays against carbapenemase-producing Klebsiella pneumoniae isolates. *Journal of Antimicrobial Chemotherapy*, **2019**, 74, 387-394	5.1	8
65	The pharmacokinetics of nitrofurantoin in healthy female volunteers: a randomized crossover study. *Journal of Antimicrobial Chemotherapy*, **2019**, 74, 1656-1661	5.1	7
64	Efficacy of single and multiple oral doses of fosfomycin against Pseudomonas aeruginosa urinary tract infections in a dynamic in vitro bladder infection model. *Journal of Antimicrobial Chemotherapy*, **2020**, 75, 1879-1888	5.1	7
63	Fosfomycin as a potential therapy for the treatment of systemic infections: a population pharmacokinetic model to simulate multiple dosing regimens. *Pharmacology Research and Perspectives*, **2018**, 6, e00378	3.1	7
62	A role for TLR1, TLR2 and NOD2 in cytokine induction by Bacteroides fragilis. *Cytokine*, **2012**, 60, 861-9	4	7
61	Rapid and reliable identification of Streptococcus anginosus group isolates to the species level by real-time PCR and melting curve analysis. *Journal of Microbiological Methods*, **2008**, 75, 372-4	2.8	7
60	Rapid and reliable real-time PCR assay for detection of the macrolide efflux gene and subsequent discrimination between its distinct subclasses mef(A) and mef(E). *Journal of Microbiological Methods*, **2005**, 60, 269-73	2.8	7

59	Assessment of Bactericidal Drug Activity and Treatment Outcome in a Mouse Tuberculosis Model Using a Clinical Beijing Strain. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	7
58	Prevention of invasive aspergillosis in AIDS by sulfamethoxazole. *Aids*, **2001**, 15, 1067-8	3.5	7
57	MIC-based dose adjustment: facts and fables-authorsSresponse. *Journal of Antimicrobial Chemotherapy*, **2018**, 73, 2585-2586	5.1	7
56	Variation of MIC measurements: the contribution of strain and laboratory variability to measurement precision-authorsSresponse. *Journal of Antimicrobial Chemotherapy*, **2019**, 74, 1761-1762	5.1	6
55	Population Pharmacokinetics of Imipenem in Critically Ill Patients: A Parametric and Nonparametric Model Converge on CKD-EPI Estimated Glomerular Filtration Rate as an Impactful Covariate. *Clinical Pharmacokinetics*, **2020**, 59, 885-898	6.2	6
54	A multicentre study to optimize echinocandin susceptibility testing of Aspergillus species with the EUCAST methodology and a broth microdilution colorimetric method. *Journal of Antimicrobial Chemotherapy*, **2020**, 75, 1799-1806	5.1	6
53	Urinary antibacterial activity of fosfomycin and nitrofurantoin at registered dosages in healthy volunteers. *International Journal of Antimicrobial Agents*, **2019**, 54, 435-441	14.3	6
52	Pathophysiology of in-vitro induced filaments, spheroplasts and rod-shaped bacteria in neutropenic mice. *Clinical Microbiology and Infection*, **2006**, 12, 1105-11	9.5	6
51	In-vitro susceptibility and molecular characterisation of macrolide resistance mechanisms among Streptococcus pneumonia isolates in The Netherlands: the DUEL 2 study. *Clinical Microbiology and Infection*, **2005**, 11, 312-8	9.5	6
50	Efficacy of Liposomal Amphotericin B against Wild-Type and Azole-Resistant Aspergillus fumigatus Isolates in Two Different Immunosuppression Models of Invasive Aspergillosis. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	5
49	A Prospective Clinical Study Characterizing the Influence of Morbid Obesity on the Pharmacokinetics of Gentamicin: Towards Individualized Dosing in Obese Patients. *Clinical Pharmacokinetics*, **2019**, 58, 1333-1343	6.2	5
48	Trends, seasonality and the association between outpatient antibiotic use and antimicrobial resistance among urinary bacteria in the Netherlands. *Journal of Antimicrobial Chemotherapy*, **2020**, 75, 2314-2325	5.1	5
47	Treatment of extensively drug-resistant Gram-negative infections in critically ill patients: Outcome of a consensus meeting at the 13th Asia-Pacific Congress of Clinical Microbiology and Infection, October 2012. *Journal of Global Antimicrobial Resistance*, **2013**, 1, 117-122	3.4	5
46	Impact of bacterial load on pharmacodynamics and susceptibility breakpoints for tigecycline and Klebsiella pneumoniae. *Journal of Antimicrobial Chemotherapy*, **2017**, 72, 172-180	5.1	5
45	Setting Clinical MIC Breakpoints from a PK/PD Point of View: It Is the Dose That Matters **2014**, 45-61		5
44	Duration of antibiotic treatment: are even numbers odd?. *Journal of Antimicrobial Chemotherapy*, **2005**, 56, 441-2	5.1	5
43	Oral immunization with polyvalent bacterial lysate and infection with Streptococcus pneumoniae: influence on interferon-gamma and PMN elastase concentrations in murine bronchoalveolar lavage fluid. *International Archives of Allergy and Immunology*, **1992**, 97, 173-7	3.7	5
42	Colistin Resistance Development Following Colistin-Meropenem Combination Therapy Versus Colistin Monotherapy in Patients With Infections Caused by Carbapenem-Resistant Organisms. *Clinical Infectious Diseases*, **2020**, 71, 2599-2607	11.6	5

41	Development and validation of a fast and sensitive UHPLC-DAD assay for the quantification of nitrofurantoin in plasma and urine. *Journal of Pharmaceutical and Biomedical Analysis*, **2019**, 174, 161-167	3.5	4
40	Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model--authorsSresponse. *Journal of Antimicrobial Chemotherapy*, **2015**, 70, 634-5	5.1	4
39	Development and multicentre validation of an agar-based screening method for echinocandin susceptibility testing of Aspergillus species. *Journal of Antimicrobial Chemotherapy*, **2019**, 74, 2247-2254	5.1	4
38	Thoughts on "Population pharmacokinetics and relationship between demographic and clinical variables and pharmacokinetics of gentamicin in neonates". *Therapeutic Drug Monitoring*, **2003**, 25, 256-7; author reply 257	3.2	4
37	The Role of New Posaconazole Formulations in the Treatment of Candida albicans Infections: Data from an Pharmacokinetic-Pharmacodynamic Model. *Antimicrobial Agents and Chemotherapy*, **2021**, 65,	5.9	4
36	General Concepts of Pharmacodynamics for Anti-infective Agents. *Methods in Pharmacology and Toxicology*, **2016**, 3-27	1.1	4
35	and Exposure-Effect Relationship of Liposomal Amphotericin B against Aspergillus fumigatus. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	3
34	Exploring the Interplay of Resistance Nodulation Division Efflux Pumps, C and D in Antimicrobial Resistance of Complex in Clinical Isolates. *Microbial Drug Resistance*, **2020**, 26, 1144-1152	2.9	3
33	Single-dose pharmacokinetics of temocillin in plasma and soft tissues of healthy volunteers after intravenous and subcutaneous administration: a randomized crossover microdialysis trial. *Journal of Antimicrobial Chemotherapy*, **2020**, 75, 2650-2656	5.1	3
32	Study protocol for an international, multicentre stepped-wedge cluster randomised trial to evaluate the impact of a digital antimicrobial stewardship smartphone application. *BMJ Open*, **2020** , 10, e033640	3	3
31	Evaluation of pooled human urine and synthetic alternatives in a dynamic bladder infection in vitro model simulating oral fosfomycin therapy. *Journal of Microbiological Methods*, **2020**, 171, 105861	2.8	3
30	Bacteroides fragilis in biopsies of patients with major abscesses and diabetic foot infections: direct molecular versus culture-based detection. *Diagnostic Microbiology and Infectious Disease*, **2016**, 85, 263-5	2.9	3
29	Polymyxin Susceptibility Testing and Breakpoint Setting. *Advances in Experimental Medicine and Biology*, **2019**, 1145, 117-132	3.6	3
28	Voriconazole efficacy against Candida glabrata and Candida krusei: preclinical data using a validated in vitro pharmacokinetic/pharmacodynamic model. *Journal of Antimicrobial Chemotherapy* , **2020**, 75, 140-148	5.1	3
27	Relationship between pharmacodynamic indices and killing patterns in vitro. *Future Microbiology*, **2011**, 6, 613-6	2.9	3
26	The Predictive Value of Laboratory Tests for Efficacy of Antibiotic Combination Therapy. *Infectious Disease and Therapy*, **2007**, 103-128		3
25	Pharmacokinetics and Pharmacodynamics of?Azoles. *Infectious Disease and Therapy*, **2007**, 327-354		3
24	Activity of Cefepime in Combination with the Novel -Lactamase Inhibitor Taniborbactam (VNRX-5133) against Extended-Spectrum--Lactamase-Producing Isolates in Checkerboard Assays. *Antimicrobial Agents and Chemotherapy*, **2021**, 65,	5.9	3

23	Multicentre testing of the EUCAST broth microdilution reference method for MIC determination on Mycobacterium tuberculosis. *Clinical Microbiology and Infection*, **2021**, 27, 288.e1-288.e4	9.5	3
22	The Effect of Antibiotic Restriction Programs on Prevalence of Antimicrobial Resistance: A Systematic Review and Meta-Analysis. *Open Forum Infectious Diseases*, **2021**, 8, ofab070	1	3
21	Toward Harmonization of Voriconazole CLSI and EUCAST Breakpoints for Candida albicans Using a Validated Pharmacokinetic/Pharmacodynamic Model. *Antimicrobial Agents and Chemotherapy*, **2020**, 64,	5.9	2
20	Continuous infusion of amphotericin B deoxycholate for the treatment of life-threatening Candida infections. *American Journal of Respiratory and Critical Care Medicine*, **2013**, 188, 1033	10.2	2
19	Controlling antimicrobial resistance: Interfering in the process of natural selection. *Antimicrobial Resistance and Infection Control*, **2013**, 2, 32	6.2	2
18	Why the AUC/MIC ratio should not be used to predict the effects of beta-lactams. *Clinical Infectious Diseases*, **2002**, 35, 209-10	11.6	2
17	In-vitro pharmacokinetic/pharmacodynamic model data suggest a potential role of new formulations of posaconazole against Candida krusei but not Candida glabrata infections. *International Journal of Antimicrobial Agents*, **2021**, 57, 106291	14.3	2
16	Pharmacokinetic/pharmacodynamic analysis of oral fosfomycin against Enterobacterales, Pseudomonas aeruginosa and Enterococcus spp. in an in vitro bladder infection model: impact on clinical breakpoints. *Journal of Antimicrobial Chemotherapy*, **2021**, 76, 3201-3211	5.1	2
15	A New Marker of Echinocandin Activity in an Pharmacokinetic/Pharmacodynamic Model Correlates with an Animal Model of Aspergillus fumigatus Infection. *Antimicrobial Agents and Chemotherapy*, **2018**, 62,	5.9	1
14	Impact of Pharmacodynamics on Dosing Schedules: Optimizing Efficacy, Reducing Resistance, and Detection of Emergence of Resistance **2005**, 387-407		1
13	Antibiotic treatment in cystic fibrosis. *Antimicrobics and Infectious Diseases Newsletter*, **2000**, 18, 25-29		1
12	Bacterial quantification in tissue homogenates from pharmacodynamic studies using growth curves. *Journal of Medical Microbiology*, **2020**, 69, 676-684	3.2	1
11	Zinc-Impregnated Mesh for Abdominal Wall Repair Reduces Infection in a Rat Model of Peritonitis. *Journal of Surgical Research*, **2020**, 246, 560-567	2.5	1
10	Excluded versus included patients in a randomized controlled trial of infections caused by carbapenem-resistant Gram-negative bacteria: relevance to external validity. *BMC Infectious Diseases*, **2021**, 21, 309	4	1
9	The synthetic synergistic cinnamon oil CIN-102 is active against Madurella mycetomatis, the most common causative agent of mycetoma. *PLoS Neglected Tropical Diseases*, **2021**, 15, e0009488	4.8	1
8	Continuous Infusion of Beta-lactam Antibiotics **2014**, 223-255		0
7	Evaluation of the post-antibiotic effect for the combination of a β-lactam antibiotic and a β-lactamase inhibitor: ceftazidime-avibactam in neutropenic mouse thigh and lung infections. *Journal of Chemotherapy*, **2021**, 33, 400-408	2.3	0
6	Colistin versus colistin plus meropenem for severe infections AuthorsSreply. *Lancet Infectious Diseases, The*, **2018**, 18, 495-496	25.5	

List of Publications

5	Shortening the incubation time for the combination disk diffusion extended-spectrum β-lactamase (ESBL) confirmation test: how far can we go?. *International Journal of Antimicrobial Agents*, **2017**, 50, 473-476	14.3
4	Antibiotic treatment in cystic fibrosis. *Antimicrobics and Infectious Diseases Newsletter*, **2000**, 18, 33-37	
3	5-Flucytosine **2009**, 307-315	
2	Pharmacodynamics of anti-infective agents **2010**, 49-59	
1	Cefpirome Treatment Results in Limited Selection of Stable Derepressed Mutants in the Intestinal Flora of Rats Treated for an Experimental Pulmonary Infection. *Microbial Drug Resistance*, **2020**, 26, 341-348	2.9